EFFICACY AND SAFETY OF ANIFROLUMAB IN PATIENTS WITH MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF THE SECOND PHASE 3 RANDOMIZED CONTROLLED TRIAL

被引：0
|
作者：
Morand, Eric F. [1 ]
Furie, Richard [2 ]
Tanaka, Yoshiya [3 ]
Bruce, Ian N. [4 ]
Askanase, Anca D. [5 ]
Richez, Christophe [6 ]
Bae, Sang-Cheol [7 ]
Brohawn, Mr Philip Z. [8 ]
Pineda, Lilia [8 ]
Berglind, Anna [9 ]
Tummala, Raj [8 ]
机构：
[1] Monash Univ, Melbourne, Vic, Australia
[2] Zucker Sch Med Hofstra Northwell, Great Neck, NY USA
[3] Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka, Japan
[4] Univ Manchester, Manchester, Lancs, England
[5] Columbia Univ, Coll Phys & Surg, New York, NY USA
[6] CHU Bordeaux GH Pellegrin, Bordeaux, France
[7] Hanyang Univ Hosp Rheumat Dis, Seoul, South Korea
[8] AstraZeneca, Gaithersburg, MD USA
[9] AstraZeneca, Gothenburg, Sweden
来源：
INTERNAL MEDICINE JOURNAL | 2020年 / 50卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
ARA-68
引用
收藏
页码：22 / 23
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial
    Morand, Eric
    Furie, Richard
    Tanaka, Yoshiya
    Bruce, Ian
    Askanase, Anca
    Riche'z, Christophe
    Bae, Sang-Cheol
    Brohawn, Philip
    Pineda, Lilia
    Berglind, Anna
    Tummala, Raj
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [2] A Phase 3 Randomized Controlled Trial of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus
    Furie, Richard
    Morand, Eric
    Bruce, Ian
    Manzi, Susan
    Kalunian, Kenneth
    Vital, Edward
    Lawrence-Ford, Theresa
    Gupta, Ramesh
    Hiepe, Falk
    Santiago, Mittermayer
    Brohawn, Philip
    Berglind, Anna
    Tummala, Raj
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [3] Evaluation of the Efficacy and Safety of Anifrolumab in Moderate-to-Severe Systemic Lupus Erythematosus
    Cingireddy, Ananya Reddy
    Ramini, Navya
    Cingireddy, Anirudh Reddy
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)
  • [4] Longitudinal Variation of Proteomic Biomarkers That Correlate with Efficacy Endpoints: Results from a Phase 3 Trial of Anifrolumab in Moderate to Severe Systemic Lupus Erythematosus
    Lazarus, Mark
    Newcombe, Paul
    Furie, Richard A.
    Brohawn, Philip
    White, Wendy
    Sinibaldi, Dominic
    Ferrari, Nicola
    Tummala, Raj
    Al-Mossawi, Hussein
    Vital, Edward
    Morand, Eric F.
    Muthas, Daniel
    Ramaswamy, Madhu
    [J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 714 - 715
  • [5] Efficacy and Safety of Epratuzumab in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized, Placebo-Controlled Trials
    Clowse, Megan E. B.
    Wallace, Daniel J.
    Furie, Richard
    Petri, Michelle
    Pike, Marilyn
    Leszczynski, Piotr
    Neuwelt, C. Michael
    Hobbs, Kathryn
    Keiserman, Mauro
    Duca, Liliana
    Kalunian, Kenneth
    Bongardt, Sabine
    Stach, Christian
    Beaudot, Carolyn
    Kilgallen, Brian
    Galateanu, Catrinel
    Gordon, Caroline
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [6] Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus
    Chia, Yen Lin
    Tummala, Raj
    Mai, Tu H.
    Rouse, Tomas
    Streicher, Katie
    White, Wendy, I
    Morand, Eric F.
    Furie, Richard A.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 62 (09): : 1094 - 1105
  • [7] Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus
    Furie, Richard
    Morand, Eric F.
    Askanase, Anca D.
    Vital, Edward M.
    Merrill, Joan T.
    Kalyani, Rubana N.
    Abreu, Gabriel
    Pineda, Lilia
    Tummala, Raj
    [J]. LUPUS, 2021, 30 (08) : 1254 - 1263
  • [8] Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus
    Chia, Yen Lin
    Zhang, Jianchun
    Tummala, Raj
    Rouse, Tomas
    Furie, Richard A.
    Morand, Eric F.
    [J]. RHEUMATOLOGY, 2022, 61 (05) : 1900 - 1910
  • [9] Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled Trial
    Merrill, Joan T.
    Tanaka, Yoshiya
    D'Cruz, David
    Vila-Rivera, Karina
    Siri, Daniel
    Zeng, Xiaofeng
    Saxena, Amit
    Aringer, Martin
    D'Silva, Kristin M.
    Cheng, Ling
    Mohamed, Mohamed-Eslam F.
    Siovitz, Lucia
    Bhatnagar, Sumit
    Gaudreau, Marie-Claude
    Doan, Thao T.
    Friedman, Alan
    [J]. ARTHRITIS & RHEUMATOLOGY, 2024,
  • [10] Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor, Fenebrutinib (GDC-0853), in Moderate to Severe Systemic Lupus Erythematosus: Results of a Phase 2 Randomized Controlled Trial
    Isenberg, David
    Furie, Richard
    Jones, Nicholas
    Guibord, Pascal
    Galanter, Joshua
    Lee, Chin
    McGregor, Anna
    Toth, Balazs
    Rae, Julie
    Hwang, Olivia
    Miranda, Pedro
    de Souza, Viviane
    Jaller-Raad, Juan
    Fernandes, Anna Maura
    Garcia Salinas, Rodrigo
    Chinn, Leslie
    Townsend, Michael
    Morimoto, Alyssa
    Tuckwell, Katie
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
12345